Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet

CONCLUSION: Etelcalcetide improved sHPT control in this group of patients, previously under cinacalcet treatment, and significantly increased plasma sclerostin concentration. The impact of etelcalcetide treatment on sclerostin levels is a novel finding.PMID:36437202 | DOI:10.1016/j.nefroe.2022.11.014

Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - November 27, 2022 Category: Urology & Nephrology Authors: Luciano Artur Lopes Pereira Catarina Meng Manuel Augusto Gon çalves Amoedo Maria Teresa de Sousa Costa Pinto Ferreira Mendes Marco Alexandre Mateus Prazeres Marques Jo ão Miguel Machado Dória Frazão Andr é Luiz Loureiro Weigert Source Type: research